Fred A. Middleton - 20 Mar 2023 Form 4 Insider Report for CalciMedica, Inc. /DE/ (CALC)

Role
Director, 10%+ Owner
Signature
By John Dunn, Attorney-in-Fact
Issuer symbol
CALC
Transactions as of
20 Mar 2023
Net transactions value
$0
Form type
4
Filing time
22 Mar 2023, 20:54:44 UTC
Previous filing
03 Oct 2022
Next filing
29 Mar 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CALC Common Stock Award +703,388 703,388 20 Mar 2023 By Sanderling Venture Partners VI, L.P. F1, F2
transaction CALC Common Stock Award +582,757 582,757 20 Mar 2023 By Sanderling Venture Partners VI Co-Investment Fund, L.P. F3, F4
transaction CALC Common Stock Award +17,682 17,682 20 Mar 2023 By Sanderling Ventures Management VI F4, F5
transaction CALC Common Stock Award +7,456 7,456 20 Mar 2023 By Sanderling VI Beteligungs GmbH & Co KG F4, F6
transaction CALC Common Stock Award +8,884 8,884 20 Mar 2023 By Sanderling VI Limited Partnership F4, F7
transaction CALC Common Stock Award +256,852 256,852 20 Mar 2023 By Sanderling Ventures VII, L.P. F8, F9
transaction CALC Common Stock Award +14,425 14,425 20 Mar 2023 By Sanderling Ventures VII Annex Fund, L.P. F10, F11
transaction CALC Common Stock Award +47,052 47,052 20 Mar 2023 By Sanderling Ventures VII (Canada), L.P. F11, F12
transaction CALC Common Stock Award +1,548 1,548 20 Mar 2023 By Sanderling Ventures Management VII F11, F13
transaction CALC Common Stock Award +8,176 8,176 20 Mar 2023 By Golden Triangle Ventures, LLC F14, F15

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CALC Warrant Award +5,760 5,760 20 Mar 2023 Common Stock 5,760 $10.42 Direct F16, F17
transaction CALC Warrant Award +2,672 2,672 20 Mar 2023 Common Stock 2,672 $26.74 By Sanderling Venture Partners VI, LP F4, F16, F18
transaction CALC Warrant Award +16,539 16,539 20 Mar 2023 Common Stock 16,539 $27.94 By Sanderling Venture Partners VI, LP F4, F16, F19
transaction CALC Warrant Award +2,685 2,685 20 Mar 2023 Common Stock 2,685 $27.94 By Sanderling Venture Partners VI, LP F4, F16, F20
transaction CALC Warrant Award +1,910 1,910 20 Mar 2023 Common Stock 1,910 $26.74 By Sanderling Venture Partners VI Co-Investment Fund, L.P. F4, F16, F21
transaction CALC Warrant Award +6,852 6,852 20 Mar 2023 Common Stock 6,852 $27.94 By Sanderling Venture Partners VI Co-Investment Fund, L.P. F4, F16, F22
transaction CALC Warrant Award +15,403 15,403 20 Mar 2023 Common Stock 15,403 $27.94 By Sanderling Venture Partners VI Co-Investment Fund, L.P. F4, F16, F23
transaction CALC Warrant Award +237 237 20 Mar 2023 Common Stock 237 $27.94 By Sanderling Ventures Management VI F4, F16, F24
transaction CALC Warrant Award +183 183 20 Mar 2023 Common Stock 183 $27.94 By Sanderling Ventures Management VI F4, F16, F25
transaction CALC Warrant Award +8,393 8,393 20 Mar 2023 Common Stock 8,393 $27.94 By Sanderling Ventures VII, LP F11, F16, F26
transaction CALC Warrant Award +12,380 12,380 20 Mar 2023 Common Stock 12,380 $27.94 By Sanderling Ventures VII, LP F11, F16, F27
transaction CALC Warrant Award +2,203 2,203 20 Mar 2023 Common Stock 2,203 $27.94 By Sanderling Ventures VII (Canada), LP F11, F16, F28
transaction CALC Warrant Award +3,249 3,249 20 Mar 2023 Common Stock 3,249 $27.94 By Sanderling Ventures VII (Canada), LP F11, F16, F29
transaction CALC Warrant Award +569 569 20 Mar 2023 Common Stock 569 $27.94 By Sanderling Ventures VII Annex Fund, L.P. F11, F16, F30
transaction CALC Warrant Award +840 840 20 Mar 2023 Common Stock 840 $27.94 By Sanderling Ventures VII Annex Fund, L.P. F11, F16, F31
transaction CALC Warrant Award +113 113 20 Mar 2023 Common Stock 113 $27.94 By Sanderling Ventures Management VII F11, F16, F32
transaction CALC Warrant Award +167 167 20 Mar 2023 Common Stock 167 $27.94 By Sanderling Ventures Management VII F11, F16, F33
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Received in exchange for 24,423,158 shares of common stock of CalciMedica, Inc. ("CalciMedica") pursuant to an Agreement and Plan of Merger and Reorganization (the "Merger Agreement") by and among CalciMedica, the Issuer and Camaro Merger Sub, Inc., a wholly-owned subsidiary of the Issuer ("Merger Sub"). Under the terms of the Merger Agreement, on March 20, 2023, Merger Sub merged with and into CalciMedica (the "Merger"), with CalciMedica surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each share of CalciMedica common stock was converted into the right to receive 0.0288 of a share of the Issuer's common stock. Subsequent to the Merger, the name of the Issuer was changed from Graybug Vision, Inc. to CalciMedica, Inc.
F2 The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the securities of the Issuer held by Sanderling Venture Partners VI, LP ("SVP VI, LP", together with Sanderling Venture Partners VI Co-Investment Fund, L.P., Sanderling VI Beteiligungs GmbH & Co. KG, Sanderling Ventures Management VI and Sanderling VI Limited Partnership (the "Sanderling VI Shares"). The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.
F3 Received in exchange for 20,234,606 shares of the common stock of CalciMedica pursuant to the Merger Agreement.
F4 The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling VI Securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.
F5 Received in exchange for 613,943 shares of the common stock of CalciMedica pursuant to the Merger Agreement.
F6 Received in exchange for 258,883 shares of the common stock of CalciMedica pursuant to the Merger Agreement.
F7 Received in exchange for 308,455 shares of the common stock of CalciMedica pursuant to the Merger Agreement.
F8 Received in exchange for 8,918,437 shares of the common stock of CalciMedica pursuant to the Merger Agreement.
F9 The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the securities of the Issuer held by Sanderling Ventures VII, LP ("SVP VII, LP", together with Sanderling Ventures Management VII, Sanderling Ventures VII (Canada), L.P. and Sanderling Ventures VII Annex Fund, L.P., the "Sanderling VII Shares"). The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.
F10 Received in exchange for 500,854 shares of the common stock of CalciMedica pursuant to the Merger Agreement.
F11 The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling VII Securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.
F12 Received in exchange for 1,633,699 shares of the common stock of CalciMedica pursuant to the Merger Agreement.
F13 Received in exchange for 53,733 shares of the common stock of CalciMedica pursuant to the Merger Agreement.
F14 Received in exchange for 283,866 shares of the common stock of CalciMedica pursuant to the Merger Agreement.
F15 The Reporting Person is a managing member of Golden Triangle Ventures LLC and may be deemed to beneficially own the securities of the Issuer held by Golden Triangle Ventures LLC. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.
F16 Immediately exercisable.
F17 Received in exchange for a warrant to purchase 200,000 shares of common stock of CalciMedica pursuant to the Merger Agreement.
F18 Received in exchange for a warrant to purchase 92,748 shares of common stock of CalciMedica pursuant to the Merger Agreement.
F19 Received in exchange for a warrant to purchase 574,296 shares of common stock of CalciMedica pursuant to the Merger Agreement.
F20 Received in exchange for a warrant to purchase 93,225 shares of common stock of CalciMedica pursuant to the Merger Agreement.
F21 Received in exchange for a warrant to purchase 66,305 shares of common stock of CalciMedica pursuant to the Merger Agreement.
F22 Received in exchange for a warrant to purchase 237,911 shares of common stock of CalciMedica pursuant to the Merger Agreement.
F23 Received in exchange for a warrant to purchase 534,815 shares of common stock of CalciMedica pursuant to the Merger Agreement.
F24 Received in exchange for a warrant to purchase 8,203 shares of common stock of CalciMedica pursuant to the Merger Agreement.
F25 Received in exchange for a warrant to purchase 6,343 shares of common stock of CalciMedica pursuant to the Merger Agreement.
F26 Received in exchange for a warrant to purchase 291,407 shares of common stock of CalciMedica pursuant to the Merger Agreement.
F27 Received in exchange for a warrant to purchase 429,837 shares of common stock of CalciMedica pursuant to the Merger Agreement.
F28 Received in exchange for a warrant to purchase 76,470 shares of common stock of CalciMedica pursuant to the Merger Agreement.
F29 Received in exchange for a warrant to purchase 112,796 shares of common stock of CalciMedica pursuant to the Merger Agreement.
F30 Received in exchange for a warrant to purchase 19,754 shares of common stock of CalciMedica pursuant to the Merger Agreement.
F31 Received in exchange for a warrant to purchase 29,139 shares of common stock of CalciMedica pursuant to the Merger Agreement.
F32 Received in exchange for a warrant to purchase 3,915 shares of common stock of CalciMedica pursuant to the Merger Agreement.
F33 Received in exchange for a warrant to purchase 5,775 shares of common stock of CalciMedica pursuant to the Merger Agreement.